{"id":"lucentis-treat-and-extend","safety":{"commonSideEffects":[{"rate":"25-30","effect":"Conjunctival hemorrhage"},{"rate":"5-10","effect":"Eye pain"},{"rate":"5-10","effect":"Floaters"},{"rate":"5-10","effect":"Intraocular pressure elevation"},{"rate":"0.05-0.1","effect":"Endophthalmitis"},{"rate":"<1","effect":"Retinal detachment"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Ranibizumab is a recombinant humanized monoclonal antibody fragment that binds and neutralizes all active forms of VEGF-A, a key driver of pathological neovascularization and vascular permeability in retinal diseases. By inhibiting VEGF signaling, it reduces fluid accumulation in the macula and slows progression of vision loss. The 'treat and extend' regimen involves variable dosing intervals based on disease activity to optimize treatment burden and efficacy.","oneSentence":"Lucentis (ranibizumab) blocks vascular endothelial growth factor (VEGF) to reduce abnormal blood vessel growth and leakage in the retina.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:53:40.101Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Neovascular (wet) age-related macular degeneration"},{"name":"Macular edema following retinal vein occlusion"},{"name":"Diabetic macular edema"},{"name":"Diabetic retinopathy"}]},"trialDetails":[{"nctId":"NCT03683251","phase":"PHASE3","title":"Extension Study for the Port Delivery System With Ranibizumab (Portal)","status":"RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2018-09-20","conditions":"Neovascular Age-Related Macular Degeneration","enrollment":1000},{"nctId":"NCT04757610","phase":"PHASE3","title":"OPT-302 With Ranibizumab in Neovascular Age-related Macular Degeneration (nAMD)","status":"TERMINATED","sponsor":"Opthea Limited","startDate":"2021-03-12","conditions":"Neovascular Age-related Macular Degeneration","enrollment":986},{"nctId":"NCT03709745","phase":"PHASE4","title":"Eylea and Lucentis for Macular Edema in Branch Retinal Vein Occlusion","status":"COMPLETED","sponsor":"St. Erik Eye Hospital","startDate":"2018-10-18","conditions":"Branch Retinal Vein Occlusion with Macular Edema","enrollment":110},{"nctId":"NCT05126966","phase":"PHASE3","title":"A Study Of The Effectiveness And Safety Of A 36-Week Refill Regimen For The Port Delivery System With Ranibizumab Vs Aflibercept Treat & Extend In Subjects With Neovascular Age-Related Macular Degeneration","status":"WITHDRAWN","sponsor":"Hoffmann-La Roche","startDate":"2023-12-29","conditions":"Neovascular Age-Related Macular Degeneration","enrollment":""},{"nctId":"NCT02640664","phase":"PHASE3","title":"Rainbow Extension Study","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2016-06-16","conditions":"Retinopathy of Prematurity (ROP)","enrollment":180},{"nctId":"NCT04698850","phase":"PHASE4","title":"Brolucizumab vs. Aflibercept for Retinal Angiomatous Proliferation","status":"WITHDRAWN","sponsor":"Faculty Hospital Kralovske Vinohrady","startDate":"2021-01-04","conditions":"Wet Macular Degeneration","enrollment":""},{"nctId":"NCT04988178","phase":"","title":"Analysis of naïve Patients With Age-related Macular Degeneration Neovascular Type and Treated With Ranibizumab (Lucentis®) in Treat-and-extend at the CHU Brugmann.","status":"COMPLETED","sponsor":"Brugmann University Hospital","startDate":"2021-04-13","conditions":"Macular Degeneration","enrollment":34},{"nctId":"NCT02222610","phase":"PHASE2","title":"Study of the Efficacy and Tolerability of Intravitreal Injections of Ranibizumab Compared to Intravitreal Injections of Ranibizumab Combined With Targeted Retinal Photocoagulation to Treat Radiation Retinopathy.","status":"COMPLETED","sponsor":"Greater Houston Retina Research","startDate":"2014-09-23","conditions":"Radiation Retinopathy","enrollment":40},{"nctId":"NCT03038880","phase":"PHASE2","title":"Study to Evaluate Faricimab (RO6867461; RG7716) for Extended Durability in the Treatment of Neovascular Age Related Macular Degeneration","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2017-01-27","conditions":"Neovascularization, Choroidal, Macular Degeneration, Age-Related","enrollment":76},{"nctId":"NCT02274259","phase":"PHASE4","title":"Comparing Injection Frequency Between Aflibercept and Ranibizumab in Patients With CRVO With a Treat& Extend Regimen","status":"COMPLETED","sponsor":"Anders Kvanta","startDate":"2014-10","conditions":"Central Retinal Vein Occlusion","enrollment":40},{"nctId":"NCT01934556","phase":"PHASE1, PHASE2","title":"A Safety and Efficacy Trial of a Treat and Extend Protocol Using Ranibizumab With and Without Laser Photocoagulation for Diabetic Macular Edema","status":"COMPLETED","sponsor":"Palmetto Retina Center, LLC","startDate":"2013-11","conditions":"Diabetic Macular Edema","enrollment":150},{"nctId":"NCT01982435","phase":"PHASE1, PHASE2","title":"Safety and Efficacy of Ranibizumab for Diabetic Macular Edema","status":"COMPLETED","sponsor":"Justis Ehlers","startDate":"2014-06-24","conditions":"Diabetic Macular Edema","enrollment":27},{"nctId":"NCT02103738","phase":"","title":"Canadian Treat and Extend Analysis Trial With Ranibizumab","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2013-05-08","conditions":"wetAMD","enrollment":505},{"nctId":"NCT01972789","phase":"PHASE4","title":"Comparison of Treatment Regimens Using Ranibizumab: Intensive (Resolution of Intra- and Sub-retinal Fluid) vs Relaxed (Resolution of Intra-retinal Fluid and/or Sub-retinal Fluid >200µm at the Foveal Centre)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2013-10-31","conditions":"Subfoveal Choroidal Neovascularization CNV Secondary to Wet Age-related Macular Degeneration AMD","enrollment":349},{"nctId":"NCT04089605","phase":"PHASE4","title":"Ranibizumab vs Dexamethasone Implant in Vitrectomized Eyes With Diabetic Macular Edema","status":"COMPLETED","sponsor":"Far Eastern Memorial Hospital","startDate":"2017-06-01","conditions":"Diabetic Macular Edema","enrollment":48},{"nctId":"NCT01775124","phase":"PHASE4","title":"Efficacy and Safety of Ranibizumab 0.5 mg Administered as Two Alternative Dosing Regimens in Chinese Patients With nAMD (Age Related Macular Degeneration)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2013-02-22","conditions":"Neovascular Age-related Macular Degeneration","enrollment":332},{"nctId":"NCT02321839","phase":"PHASE4","title":"Evaluation of the Usefulness of a Treat and Extend Regimen Using Ranibizumab for Neovascular AMD.","status":"COMPLETED","sponsor":"Nagoya City University","startDate":"2014-01","conditions":"Neovascular Age-related Macular Degeneration","enrollment":78},{"nctId":"NCT02262260","phase":"PHASE3","title":"Compare Safety/Efficacy of Labeled vs Wait-Extend Regimen of Lucentis in Turkish Patients With VI Due to DME","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2014-12-12","conditions":"Diabetic Macular Edema","enrollment":87},{"nctId":"NCT02130024","phase":"PHASE4","title":"A Comparison of Ranibizumab and Aflibercept for the Development of Geographic Atrophy in (Wet) AMD Patients","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2014-04-11","conditions":"Age-Related Macular Degeneration","enrollment":281},{"nctId":"NCT01748292","phase":"PHASE3","title":"Treat & Extend Treatment With 0.5mg Ranibizumab vs Monthly Treatment With 0.5mg Ranibizumab","status":"COMPLETED","sponsor":"Charles C Wykoff, PhD, MD","startDate":"2012-12","conditions":"Macular Degeneration","enrollment":60},{"nctId":"NCT01476449","phase":"PHASE2","title":"Dosing Study of Ranibizumab for Diabetic Retinal and Macular Edema","status":"COMPLETED","sponsor":"Retina Vitreous Associates of Florida","startDate":"2011-11","conditions":"Diabetic Retinopathy, Macular Edema","enrollment":20},{"nctId":"NCT03944070","phase":"NA","title":"Management of Patients With Neovascular Age-related Macular Degeneration Undergoing Cataract Surgery","status":"UNKNOWN","sponsor":"Ophthalmica Eye Institute","startDate":"2018-01-01","conditions":"Wet Macular Degeneration, Cataract Extraction","enrollment":16},{"nctId":"NCT02309281","phase":"PHASE4","title":"Intravitreal Aflibercept in Neovascular AMD With Limited Response to Ranibizumab","status":"COMPLETED","sponsor":"Vista Klinik","startDate":"2013-05","conditions":"Neovascular Age-related Macular Degeneration","enrollment":33},{"nctId":"NCT03059277","phase":"PHASE4","title":"Intravitreal Alfibercept for Center Involved DME Previously Managed With Intravitreal Ranibizumab","status":"WITHDRAWN","sponsor":"Southeast Clinical Research Associates, LLC","startDate":"2018-06-01","conditions":"Diabetic Macular Edema","enrollment":""},{"nctId":"NCT01863199","phase":"PHASE4","title":"Impact of Home Monitoring to Decrease the Treatment Burden for Neovascular Age-related Macular Degeneration (AMD)","status":"COMPLETED","sponsor":"Retinal Consultants of Arizona","startDate":"2013-05","conditions":"Neovascular Age Related Macular Degeneration","enrollment":60},{"nctId":"NCT00473330","phase":"PHASE3","title":"A Study of Ranibizumab Injection in Subjects With Clinically Significant Macular Edema (ME) With Center Involvement Secondary to Diabetes Mellitus (RISE)","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2007-06","conditions":"Diabetes Mellitus, Macular Edema","enrollment":377},{"nctId":"NCT01948830","phase":"PHASE3","title":"Randomized Study for Efficacy and Safety of Ranibizumab 0.5mg in Treat-extend and Monthly Regimens in Patients With nAMD","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2013-12-17","conditions":"Age-related Macular Degeneration, Choroidal Neovascularization","enrollment":650},{"nctId":"NCT00473382","phase":"PHASE3","title":"A Study of Ranibizumab Injection in Subjects With Clinically Significant Macular Edema (ME) With Center Involvement Secondary to Diabetes Mellitus (RIDE)","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2007-06","conditions":"Diabetes Mellitus, Macular Edema","enrollment":382},{"nctId":"NCT01297569","phase":"PHASE4","title":"Ranibizumab \"Treat and Extend\" in Diabetic Macular Edma","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2011-01","conditions":"Diabetic Macular Edema","enrollment":7},{"nctId":"NCT01942213","phase":"","title":"Observational Study to Evaluate and Compare the Rate and Extent of Inflammation After a Single Intravitreal Injection of Ranibizumab vs. a Single Intravitreal Injection of Aflibercept in Treatment Naive and Treatment Experienced Patients.","status":"COMPLETED","sponsor":"Prism Vision Group","startDate":"2013-12","conditions":"Neovascular Age Related Macular Degeneration","enrollment":136},{"nctId":"NCT01580020","phase":"PHASE4","title":"Extension Study to Compare Long-term Efficacy and Safety of Ranibizumab Intravitreal Injections Versus Dexamethasone Intravitreal Implant in Patients With RVO","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2012-05","conditions":"Retinal Vein Occlusion","enrollment":175},{"nctId":"NCT02522897","phase":"PHASE4","title":"Evaluation of the \"Treat-and-extend\" Scheme in Patients With Retinal Vein Occlusion (RVO) With and Without LASER Treatment of Ischaemic Retinal Areas","status":"UNKNOWN","sponsor":"PD. Dr. med. Armin Wolf","startDate":"2015-08","conditions":"Central Retinal Vein Occlusion With Macular Edema","enrollment":60},{"nctId":"NCT01500915","phase":"PHASE4","title":"FUSION Regimen: Combined Pro re Nata and Fixed Regimen Ranibizumab in Exudative Age-related Macular Degeneration","status":"COMPLETED","sponsor":"Institut de la Macula y la Retina","startDate":"2010-11","conditions":"Exudative Age-related Macular Degeneration","enrollment":17},{"nctId":"NCT02328209","phase":"NA","title":"Evaluation of the Simplified Treat And Extend Regimen Using Ranibizumab in Exudative Age Related Macular Degeneration","status":"UNKNOWN","sponsor":"Mie University","startDate":"2014-06","conditions":"Exudative Age-related Macular Degeneration","enrollment":50},{"nctId":"NCT01171976","phase":"PHASE3","title":"Efficacy and Safety of Ranibizumab in Two \"Treat and Extend\" Treatment Algorithms Versus Ranibizumab As Needed in Patients With Macular Edema and Visual Impairment Secondary to Diabetes Mellitus","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2010-09","conditions":"Diabetic Macular Edema","enrollment":373},{"nctId":"NCT00095433","phase":"PHASE3","title":"Extension Study of rhuFab V2 in Subjects With Neovascular Age-Related Macular Degeneration (AMD)","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2002-09","conditions":"Macular Degeneration","enrollment":100},{"nctId":"NCT01198327","phase":"PHASE3","title":"Extended Follow-up of Patients With Macular Edema Due to Retinal Vein Occlusion","status":"COMPLETED","sponsor":"Peter A Campochiaro, MD","startDate":"2010-08","conditions":"Retinal Vein Occlusion","enrollment":66},{"nctId":"NCT01256827","phase":"","title":"Seven Year Update of Macular Degeneration Patients","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2010-12","conditions":"Age-related Macular Degeneration","enrollment":65},{"nctId":"NCT01148511","phase":"PHASE4","title":"Comparison of Safety, Effectiveness and Quality of Life Outcomes Between Labeled Versus \"Treat and Extend\" Regimen in Turkish Patients With Choroidal Neovascularisation Due to Age-related Macular Degeneration (AMD)","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2010-02","conditions":"Age-related Macular Degeneration","enrollment":99},{"nctId":"NCT00687804","phase":"PHASE3","title":"A 12 Month Core Study to Assess the Efficacy and Safety of Ranibizumab (Intravitreal Injections) in Patients With Visual Impairment Due to Diabetic Macular Edema and a 24 Month Open-label Extension Study","status":"COMPLETED","sponsor":"Novartis","startDate":"2008-05","conditions":"Diabetic Macular Edema","enrollment":345},{"nctId":"NCT01453920","phase":"PHASE4","title":"Wet AMD Recurrence Rate in Patients Stable on Three Month Ranibizumab Dosing","status":"COMPLETED","sponsor":"University Health Network, Toronto","startDate":"2011-11","conditions":"Age Related Macular Degeneration","enrollment":44}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":311,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Lucentis (Treat and extend)","genericName":"Lucentis (Treat and extend)","companyName":"Retinal Consultants of Arizona","companyId":"retinal-consultants-of-arizona","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Lucentis (ranibizumab) is used to treat conditions such as Wet Macular Degeneration, Diabetic Macular Edema, and Retinal Vein Occlusion. It is administered in a treatment and extend regimen, which involves regular injections of the medication.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}